RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032
Overview
The RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market is expected to reach a 6.57 USD Million by 2032 and is projected to grow at a CAGR of 7.47% from 2025 to 2032.
Revenue, 2024 (USD Million)
3.70
Forecast, 2032 (USD Million)
6.57
CAGR, 2024 - 2032
7.47%
Report Coverage
RoE
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market 2018-2032 USD Million
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 3.70 USD Million
- Projected Market Size (2032): 6.57 USD Million
- CAGR (2025-2032): 7.47%
Key Findings of RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market
- The RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at 3.70 USD Million in 2024.
- The RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market is likely to grow at a CAGR of 7.47% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Beta Emitters in Isotope Segment accounted for the largest share of the market with a revenue of 3.18 USD Million
- The fastest growing segment Small Molecule Ligands in Vector Type Segment grew Fastest with a CAGR of 8.04% during the forecast period from 2024 to 2032.
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market Scope
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market Segmentation & Scope
Isotope
- Alpha Emitters
- Beta Emitters
Sources
- Others
- Generator-Produced Isotopes
- Reactor-Produced Isotopes
End User
- Research Institutes
- Radiopharmacies
- Hospitals
Therapeutic Application
- Others
- Oncology
Vector Type
- Others
- Monoclonal Antibodies
- Peptides
- Small Molecule Ligands
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2024 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 3.70 USD Million |
| Market Value in 2032 | 6.57 USD Million |
| CAGR (2025-2032) | 7.47% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Isotope,Sources,End User,Therapeutic Application,Vector Type |
Regional Insights:
-
Leading Market (2024-2032): RoE, leading in terms of revenue 3.70 USD Million in 2024
- Key Country: RoE, leading in terms of revenue with value of 3.70 USD Million in 2024.
Segments and Scope
-
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Isotope
- Beta Emitters is the largest segment in RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 3.18 USD Million in the year 2024.
- Beta Emitters is the Fastest growing segment in RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 7.51 % in forecast period 2025-2032.
-
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Sources
- Reactor-Produced Isotopes is the largest segment in RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 2.32 USD Million in the year 2024.
- Reactor-Produced Isotopes is the Fastest growing segment in RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 7.60 % in forecast period 2025-2032.
-
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By End User
- Hospitals is the largest segment in RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 2.13 USD Million in the year 2024.
- Hospitals is the Fastest growing segment in RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 7.60 % in forecast period 2025-2032.
-
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Therapeutic Application
- Oncology is the largest segment in RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 2.86 USD Million in the year 2024.
- Oncology is the Fastest growing segment in RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 7.79 % in forecast period 2025-2032.
-
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Vector Type
- Small Molecule Ligands is the largest segment in RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 1.94 USD Million in the year 2024.
- Small Molecule Ligands is the Fastest growing segment in RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 8.04 % in forecast period 2025-2032.
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Share Analysis
| Company Name |
|
||
| Novartis AG | |||
| Eckert & Ziegler | |||
| ITM Isotope Technologies Munich SE | |||
| SHINE Technologies, LLC | |||
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market Geographical Sales Distribution, 2018-2032 USD Million
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market is segmented based on Segmentation Isotope,Sources,End User,Therapeutic Application,Vector Type.
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at USD 3.70(Revenue in USD Million) in 2024.
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market is projected to grow at a CAGR of 7.47% during the forecast period of 2024 to 2032.
The Beta Emitters segment is expected to dominate the RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market, holding a largest market share of 3.18 USD Million in 2024
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market Scope
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market Segmentation & Scope
Isotope
- Alpha Emitters
- Beta Emitters
Sources
- Others
- Generator-Produced Isotopes
- Reactor-Produced Isotopes
End User
- Research Institutes
- Radiopharmacies
- Hospitals
Therapeutic Application
- Others
- Oncology
Vector Type
- Others
- Monoclonal Antibodies
- Peptides
- Small Molecule Ligands
Frequently Asked Questions
The RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market is segmented based on Segmentation Isotope,Sources,End User,Therapeutic Application,Vector Type.
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at USD 3.70(Revenue in USD Million) in 2024.
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market is projected to grow at a CAGR of 7.47% during the forecast period of 2024 to 2032.
The estimated market value of the RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market for final year is USD 6.57 (USD Million).
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling
Frequently Asked Questions
The RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market is segmented based on Segmentation Isotope,Sources,End User,Therapeutic Application,Vector Type.
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at USD 3.70(Revenue in USD Million) in 2024.
RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market is projected to grow at a CAGR of 7.47% during the forecast period of 2024 to 2032.
The estimated market value of the RoE Alpha and Beta Emitters Based Radiopharmaceuticals Market for final year is USD 6.57 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.